Your browser doesn't support javascript.
loading
The Canadian Rare Diseases Models and Mechanisms (RDMM) Network: Connecting Understudied Genes to Model Organisms.
Boycott, Kym M; Campeau, Philippe M; Howley, Heather E; Pavlidis, Paul; Rogic, Sanja; Oriel, Christine; Berman, Jason N; Hamilton, Robert M; Hicks, Geoffrey G; Lipshitz, Howard D; Masson, Jean-Yves; Shoubridge, Eric A; Junker, Anne; Leroux, Michel R; McMaster, Christopher R; Michaud, Jaques L; Turvey, Stuart E; Dyment, David; Innes, A Micheil; van Karnebeek, Clara D; Lehman, Anna; Cohn, Ronald D; MacDonald, Ian M; Rachubinski, Richard A; Frosk, Patrick; Vandersteen, Anthony; Wozniak, Richard W; Pena, Izabella A; Wen, Xiao-Yan; Lacaze-Masmonteil, Thierry; Rankin, Catharine; Hieter, Philip.
Affiliation
  • Boycott KM; CHEO Research Institute, University of Ottawa, Ottawa, ON K1H 8L1, Canada. Electronic address: kboycott@cheo.on.ca.
  • Campeau PM; Centre de Recherche du CHU Ste-Justine, Department of Pediatrics, Université de Montréal, Montréal, QC H3T 1C5, Canada.
  • Howley HE; CHEO Research Institute, University of Ottawa, Ottawa, ON K1H 8L1, Canada.
  • Pavlidis P; Michael Smith Laboratories, University of British Columbia, Vancouver, BC V6T 1Z4, Canada; Department of Psychiatry, University of British Columbia, Vancouver, BC V6T 1Z4, Canada.
  • Rogic S; Michael Smith Laboratories, University of British Columbia, Vancouver, BC V6T 1Z4, Canada; Department of Psychiatry, University of British Columbia, Vancouver, BC V6T 1Z4, Canada.
  • Oriel C; Maternal Infant Child and Youth Research Network (MICYRN), Vancouver, BC V5Z 4H4, Canada.
  • Berman JN; CHEO Research Institute, University of Ottawa, Ottawa, ON K1H 8L1, Canada.
  • Hamilton RM; Labatt Family Heart Centre and Translational Medicine, Hospital for Sick Children, Toronto, ON M5G 1X8, Canada.
  • Hicks GG; Regenerative Medicine Program, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB R3E 3P5, Canada; Department of Biochemistry and Medical Genetics, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB R3E
  • Lipshitz HD; Department of Molecular Genetics, University of Toronto, Toronto, ON M5S 1A8, Canada.
  • Masson JY; Oncology Division, CHU de Québec-Université Laval, Laval University Cancer Research Center, Quebec City, QC, G1R 3S3, Canada.
  • Shoubridge EA; Department of Human Genetics, Montreal Neurological Institute, McGill University, Montreal, QC H3A 2B4, Canada.
  • Junker A; Department of Pediatrics, British Columbia Children's Hospital Research Institute, University of British Columbia, Vancouver, BC V6H 3N1, Canada.
  • Leroux MR; Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC V5A 1S6, Canada.
  • McMaster CR; Department of Pharmacology, Dalhousie University, Halifax, NS B3H 4R2, Canada.
  • Michaud JL; Centre de Recherche du CHU Ste-Justine, Department of Pediatrics, Université de Montréal, Montréal, QC H3T 1C5, Canada.
  • Turvey SE; Department of Human Genetics, Montreal Neurological Institute, McGill University, Montreal, QC H3A 2B4, Canada.
  • Dyment D; CHEO Research Institute, University of Ottawa, Ottawa, ON K1H 8L1, Canada.
  • Innes AM; Department of Medical Genetics, Cumming School of Medicine, University of Calgary, Alberta Children's Hospital, Calgary, AB T2N 4N1, Canada.
  • van Karnebeek CD; Department of Human Genetics, Montreal Neurological Institute, McGill University, Montreal, QC H3A 2B4, Canada; Department of Pediatrics, Amsterdam University Medical Centres, Amsterdam, the Netherlands; Department of Clinical Genetics, Amsterdam University Medical Centres, Amsterdam, the Netherland
  • Lehman A; Department of Medical Genetics, University of British Columbia, Vancouver, BC V6H 3N1, Canada.
  • Cohn RD; Genetics and Genome Biology Program, SickKids Research Institute, Department of Paediatrics and Molecular Genetics, University of Toronto, Toronto, ON M5G 0A4, Canada.
  • MacDonald IM; Department of Ophthalmology and Visual Sciences, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2R7, Canada.
  • Rachubinski RA; Genetics and Genome Biology Program, SickKids Research Institute, Department of Paediatrics and Molecular Genetics, University of Toronto, Toronto, ON M5G 0A4, Canada.
  • Frosk P; Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, MB R3A 1S1, Canada.
  • Vandersteen A; Department of Pediatrics, Maritime Medical Genetics Service, Dalhousie University, IWK Health Centre, Halifax, NS B3K 6R8, Canada.
  • Wozniak RW; Department of Cell Biology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2H7, Canada.
  • Pena IA; CHEO Research Institute, University of Ottawa, Ottawa, ON K1H 8L1, Canada.
  • Wen XY; Zebrafish Centre for Advanced Drug Discovery, Keenan Research Centre for Biomedical Science, St Michael's Hospital, Unity Health Toronto, Department of Medicine, University of Toronto, Toronto, ON M5B 1T8.
  • Lacaze-Masmonteil T; Maternal Infant Child and Youth Research Network (MICYRN), Vancouver, BC V5Z 4H4, Canada; Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada.
  • Rankin C; Department of Psychology, University of British Columbia, Vancouver, BC V6T 1Z4, Canada.
  • Hieter P; Michael Smith Laboratories, University of British Columbia, Vancouver, BC V6T 1Z4, Canada. Electronic address: hieter@msl.ubc.ca.
Am J Hum Genet ; 106(2): 143-152, 2020 02 06.
Article de En | MEDLINE | ID: mdl-32032513
ABSTRACT
Advances in genomics have transformed our ability to identify the genetic causes of rare diseases (RDs), yet we have a limited understanding of the mechanistic roles of most genes in health and disease. When a novel RD gene is first discovered, there is minimal insight into its biological function, the pathogenic mechanisms of disease-causing variants, and how therapy might be approached. To address this gap, the Canadian Rare Diseases Models and Mechanisms (RDMM) Network was established to connect clinicians discovering new disease genes with Canadian scientists able to study equivalent genes and pathways in model organisms (MOs). The Network is built around a registry of more than 500 Canadian MO scientists, representing expertise for over 7,500 human genes. RDMM uses a committee process to identify and evaluate clinician-MO scientist collaborations and approve 25,000 Canadian dollars in catalyst funding. To date, we have made 85 clinician-MO scientist connections and funded 105 projects. These collaborations help confirm variant pathogenicity and unravel the molecular mechanisms of RD, and also test novel therapies and lead to long-term collaborations. To expand the impact and reach of this model, we made the RDMM Registry open-source, portable, and customizable, and we freely share our committee structures and processes. We are currently working with emerging networks in Europe, Australia, and Japan to link international RDMM networks and registries and enable matches across borders. We will continue to create meaningful collaborations, generate knowledge, and advance RD research locally and globally for the benefit of patients and families living with RD.
Sujet(s)
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Marqueurs génétiques / Enregistrements / Maladies rares / Modèles animaux de maladie humaine Type d'étude: Prognostic_studies Limites: Animals / Humans Langue: En Journal: Am J Hum Genet Année: 2020 Type de document: Article

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Marqueurs génétiques / Enregistrements / Maladies rares / Modèles animaux de maladie humaine Type d'étude: Prognostic_studies Limites: Animals / Humans Langue: En Journal: Am J Hum Genet Année: 2020 Type de document: Article
...